JP2025509769A5 - - Google Patents
Info
- Publication number
- JP2025509769A5 JP2025509769A5 JP2024555187A JP2024555187A JP2025509769A5 JP 2025509769 A5 JP2025509769 A5 JP 2025509769A5 JP 2024555187 A JP2024555187 A JP 2024555187A JP 2024555187 A JP2024555187 A JP 2024555187A JP 2025509769 A5 JP2025509769 A5 JP 2025509769A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- ltbr
- modified
- nucleic acid
- lymphocytes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263320100P | 2022-03-15 | 2022-03-15 | |
| US63/320,100 | 2022-03-15 | ||
| PCT/US2023/064452 WO2023178187A2 (en) | 2022-03-15 | 2023-03-15 | Methods and compositions comprising fusion proteins for improved immunotherapies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025509769A JP2025509769A (ja) | 2025-04-11 |
| JP2025509769A5 true JP2025509769A5 (enExample) | 2026-03-24 |
Family
ID=88024439
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024555187A Pending JP2025509769A (ja) | 2022-03-15 | 2023-03-15 | 改善した免疫療法のための融合タンパク質を含む方法及び組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250195572A1 (enExample) |
| EP (1) | EP4493201A4 (enExample) |
| JP (1) | JP2025509769A (enExample) |
| KR (1) | KR20250005563A (enExample) |
| CN (1) | CN119343456A (enExample) |
| AU (1) | AU2023236288A1 (enExample) |
| CA (1) | CA3245638A1 (enExample) |
| IL (1) | IL315188A (enExample) |
| MX (1) | MX2024011334A (enExample) |
| WO (1) | WO2023178187A2 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025242168A1 (en) * | 2024-05-22 | 2025-11-27 | Nanjing Legend Biotech Co., Ltd. | Methods of making cells expressing an engineered receptor |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2778651T3 (es) * | 2015-10-09 | 2020-08-11 | Miltenyi Biotec Technology Inc | Receptores de antígeno quimérico y métodos de uso |
| US12083148B2 (en) * | 2017-02-22 | 2024-09-10 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | IL13Ra2-binding chimeric antigen receptors |
| CA3129263A1 (en) * | 2019-02-08 | 2020-08-13 | Dna Twopointo Inc. | Transposon-based modifications of immune cells |
| KR102957801B1 (ko) * | 2019-06-27 | 2026-04-28 | 주식회사 유틸렉스 | 4-1bb 공동자극 도메인을 갖는 키메라 항원 수용체 |
| CN114651068B (zh) * | 2019-09-16 | 2024-09-13 | 麦克马斯特大学 | 嵌合共刺激受体及其方法和用途 |
-
2023
- 2023-03-15 US US18/843,949 patent/US20250195572A1/en active Pending
- 2023-03-15 JP JP2024555187A patent/JP2025509769A/ja active Pending
- 2023-03-15 EP EP23771639.4A patent/EP4493201A4/en active Pending
- 2023-03-15 WO PCT/US2023/064452 patent/WO2023178187A2/en not_active Ceased
- 2023-03-15 AU AU2023236288A patent/AU2023236288A1/en active Pending
- 2023-03-15 IL IL315188A patent/IL315188A/en unknown
- 2023-03-15 CN CN202380041860.7A patent/CN119343456A/zh active Pending
- 2023-03-15 KR KR1020247034069A patent/KR20250005563A/ko active Pending
- 2023-03-15 CA CA3245638A patent/CA3245638A1/en active Pending
-
2024
- 2024-09-13 MX MX2024011334A patent/MX2024011334A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102946697B1 (ko) | 키메라 분자 및 그의 용도 | |
| US20210269502A1 (en) | Tumor-specific ifna secretion by car t-cells to reprogram the solid tumor microenvironment | |
| AU2024205827A1 (en) | Expression of novel cell tags | |
| KR102965095B1 (ko) | 면역 세포에서 발현되는 막-결합 항-사이토카인 비-신호전달 결합제를 이용한 인간 사이토카인의 중화 | |
| JP2021530217A5 (enExample) | ||
| JP2002509430A (ja) | Ｔｎｆスーパーファミリーのメンバーであるｎｆ−ｋａｐｐａ ｂの受容体アクティベーターに対するリガンド | |
| CN110357953B (zh) | 识别人巨细胞病毒pp65抗原的TCR | |
| JP2021525534A5 (enExample) | ||
| KR20180043841A (ko) | 키메라 항원 수용체 및 이의 용도 | |
| TWI222453B (en) | Ligand for herpes simplex virus entry mediator and methods of use | |
| JPH06501456A (ja) | 表面複合リンホトキシン | |
| KR20250068626A (ko) | Nk 세포 자극을 위한 다중특이적 항원 결합 단백질 및 이의 용도 | |
| JP2018512154A5 (enExample) | ||
| JP2005523681A5 (enExample) | ||
| JP2024514355A5 (enExample) | ||
| JP2023527613A (ja) | Ｇ１２ｖ変異を有するｒａｓに対するｈｌａクラスｉｉ拘束性ｔ細胞受容体 | |
| CN116239692B (zh) | 分离的抗体、包含该抗体的car及其用途 | |
| RU2757353C1 (ru) | NK-клеточная линия, экспрессирующая PSMA-специфический химерный антигенный рецептор и секретирующая блокатор взаимодействия CD47/SIRPa | |
| JPH06510419A (ja) | インターフェロン−γに誘発されるモノカイン−ＭＩＧ | |
| JPH07505524A (ja) | Ｉｆｎ受容体認識因子，そのタンパク質配列および使用方法 | |
| CN111100875B (zh) | TGF-β受体II同种型、融合肽、治疗方法和体外方法 | |
| WO2005024027A1 (ja) | 抗体医薬 | |
| EP4382119A1 (en) | A kit for use in the treatment of hematological cancer | |
| CN117165568B (zh) | 工程化改造的psd蛋白、细胞外囊泡及其制备方法和应用 | |
| CN104961833A (zh) | 一种人源NKp80-Fc融合蛋白及其制备方法和在肿瘤治疗中的应用 |